IMBiologics KRX:493280KOSDAQ
아이엠바이오로직스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked0since Sep 11
In Q2 2026, IMBiologics reported an operating loss of ₩2.7bn. IMBiologics (아이엠바이오로직스) appeared in 0 Korean news articles and 1 DART filing over the past seven days.
IMBiologics quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | – | – | −₩2.7bn | −₩2.1bn |
| Q1 2026 | ₩7.2bn | +74494.1% | ₩2.7bn | ₩3.8bn |
| Q2 2025 | ₩15m | – | −₩2.6bn | −₩10.7bn |
| Q1 2025 | ₩10m | – | −₩1.9bn | ₩6.9bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
IMBiologics top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest IMBiologics news Korean headlines
No articles yet.